Characteristics | MFH (n = 52) | EHF (n = 30) | P | Total (n = 82) |
---|---|---|---|---|
Age, median (range) | 68 (44–85) | 68 (46–80) | .464 | 68 (44–85) |
ECOG PS | ||||
0 | 10 (19%) | 10 (33%) | .249a) | 20 (24%) |
1 | 41 (79%) | 20 (67%) | 61 (75%) | |
2 | 1 (2%) | 0 | 1 (1%) | |
Gleason score | ||||
≤ 6 | 35 (67%) | 17 (57%) | .544a) | 52 (63%) |
7 | 14 (27%) | 10 (33%) | 24 (29%) | |
8–10 | 3 (6%) | 3 (10%) | 6 (7%) | |
Initial PSA (ng/ml) | ||||
< 10 | 36 (69%) | 19 (63%) | .203a) | 55 (67%) |
10–20 | 12 (23%) | 11 (37%) | 23 (28%) | |
> 20 | 4 (8%) | 0 (0%) | 4 (5%) | |
T stage | ||||
T1 | 20 (38%) | 9 (30%) | .362b) | 29 (35%) |
T2 | 25 (48%) | 19 (63%) | 44 (54%) | |
T3 | 7 (13%) | 2 (7%) | 9 (11%) | |
NCCN Risk group | ||||
Low | 21 (40%) | 7 (23%) | .131b) | 28 (34%) |
Intermediate | 19 (37%) | 18 (60%) | 37 (45%) | |
High | 12 (23%) | 5 (17%) | 17 (21%) |